Combined MEK and YAP inhibition in a mouse model of neuroblastoma: A promising approach for minimal residual disease
Topic overview
This study investigates combined MEK and YAP inhibition as a strategy to overcome resistance in high-risk neuroblastoma treatment. Using a mouse model mimicking post-surgical minimal residual disease, researchers address the challenge of YAP-mediated resistance that develops during long-term trametinib therapy.
Key takeaways
- Trametinib (MEK inhibitor) shows efficacy in neuroblastoma models and prolongs survival in minimal residual disease settings.
- Long-term trametinib monotherapy leads to resistance via YAP activation in the Hippo pathway.
- Combined MEK and YAP inhibition may overcome resistance mechanisms in high-risk neuroblastoma treatment.
- Minimal residual disease mouse models effectively mimic post-surgical residual tumor for therapy testing.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Combined MEK and YAP inhibition in a mouse model of neuroblastoma: A promising approach for minimal residual disease. GlobalCastMD Medical Library. 2025-10-30. https://library.globalcastmd.com/article/11180
Comments